Drug: Asacol
Generic: Mesalamine
The company: Warner Chilcott ($WCRX), UCB and Zeria Pharmaceutical
Patent expiration date: July 30, 2013
Estimated Global Sales 2012: $891 million

The scoop: Warner Chilcott is facing an issue of growth potential. The company's second-largest product, Actonel, lost patent exclusivity in Europe. The drug saw declining prescriptions in the U.S., too. And now the company's largest product, the ulcerative colitis drug Asacol, is headed off patent come July. Though we have yet to see Warner Chilcott's third quarter report, we do know Asacol sales have been flat. The drug is estimated to make $891 million globally this year. Whether its successor, Asacol HD, will manage to grow sales further remains to be seen. The company tends to rely on small advancements on current products to move forward.

For more:
Interested shoppers prompt Warner to weigh sale options


Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.